Category Archives: Advertising

Chats Not Charts: Three Steps to Pharma Post-Marketing

by Andrew Spong (originally published on stwem.com) The air of despondency that is descending over the pharmaceutical industry’s use of social media is perverse. It has nothing to do with a putative (and also fictive) absence of interest on the patient’s part in connecting with the pharmaceutical industry. It has everything to do with the […]
Also posted in E-Media, Guest Blog, leadership, Marketing, Patient Communication, patient education, social media, Strategy | Leave a comment

Pharma Marketers: Avoid the Tactical Scrum

by Al Topin With the introduction of every new technology, tactic, or gimmick comes what I call a tactical scrum. It’s like watching young kids play their first game of T-ball or soccer. No matter how much instruction the coach gives on field position or game play, the second that ball is hit or kicked, […]
Also posted in Agency Insight, E-Media, Guest Blog, Marketing, People, Sales, social media, Strategy, Technology | Tagged , , , | Leave a comment

Marijuana Doctors's Direct-to-Consumer Weed

A milestone of sorts took place on Monday March 3 when MarijuanaDoctors.com began airing a television commercial that looks to be the first ever marijuana commercial on a major TV network. The spot began airing in New Jersey and is believed to be the first time that any major television network in the U.S. has […]
Also posted in Marketing | Tagged , , , | Leave a comment

Compliance Congress: Walking the Line

Pharma industry executives, FDA officials and Department of Justice attorneys speaking last week at CBI’s 11th annual Pharmaceutical Compliance Congress (PCC) offered solutions and threats to companies hoping to avoid enforcement actions.
Also posted in compliance, Emerging Markets, FDA, Global, Legal, Manufacturing, Marketing, People, Regulatory, Sales, Strategy, Technology | Tagged , , , , , , , , , , , , , | Leave a comment

FDA Guidances, OIG Investigations to Shape Drug Marketing, Research

Marketers may see further advice from the Food and Drug Administration in the coming year that clarifies how they can use social media. Priority topics:  presenting risk and benefit information in limited space; correcting independent/third party misinformation about a drug or medical device; and appropriate use of links, according to the agenda for the Center […]
Also posted in Biotech, E-Media, FDA, Legal, pricing, Regulatory, social media | Tagged , , , , , , , | Leave a comment
  • Categories

  • Meta